New weight loss drug target reduces appetite and burns calories without sickness
The discovery could lead to a new treatment for millions of people with obesity and type 2 diabetes who do not respond well ...
Messenger-Inquirer23h
Kentucky Has the Highest Rate of GLP-1 Use in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
HealthDay on MSN16h
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...
Hims & Hers launches GLP-1 shortage tracker in its battle with the FDA
Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...
WebMD20h
New Guidance for Patients Taking GLP-1 Drugs Before Surgery
As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...
Becker's Hospital Review23h
GLP-1, SGLT2s lower mortality risk by 74% in stroke survivors: Study
Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...
Oncology Nurse Advisor16h
ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer
Findings seen in people with type 2 diabetes. HealthDay News — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in ...